For instance, pCR rate was significantly higher in HER2-E than in other subtypes (45.5% vs. 13.8%, p = 0.042) in a phase II PerELISA trial in HR+/HER2 BC patients receiving neoadjuvant pertuzumab trastuzumab and letrozol [27]. Here, ERBB2 is linked to breast cancer.